Darglitazone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Darglitazone
Darglitazone structure.svg
Legal status
Legal status
  • Development terminated
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C23H20N2O4S
Molar mass 420.481 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.[1]

Its development was terminated on November 08, 1999.[2]

Synthesis[edit]

Synthesis of darglitazone







References[edit]

  1. ^ Hulin, Bernard; Clark, David A.; Goldstein, Steven W.; McDermott, Ruth E.; Dambek, Paul J.; Kappeler, Werner H.; Lamphere, Charles H.; Lewis, Diana M.; Rizzi, James P. (1992). "Novel thiazolidine-2,4-diones as potent euglycemic agents". Journal of Medicinal Chemistry. 35 (10): 1853–64. doi:10.1021/jm00088a022. PMID 1588563.
  2. ^ "Drug Profile: Darglitazone". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 28 November 2015.